HMGB1 and Alzheimer disease: Studies investigating agents targeting specific inflammatory mediators such as TNF-α, TREM2, and cluster of differentiation 33 (CD33) have shown promise in AD, while inhibitors of Toll-like receptor 3 (TLR3), TLR4, and anti-high mobility group box-1 (HMGB1) have demonstrated positive effects on seizures.